Exelixis Inc

NASDAQ:EXEL   2:21:18 PM EDT
22.36
-0.13 (-0.58%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.78B
Current PE32.63
Forward PE 17.89
2yr Forward PE 14.43
See more stats
Estimates Current Quarter
Revenue$453.8 Million
Adjusted EPS$0.23
See more estimates
10-Day MA$22.85
50-Day MA$22.42
200-Day MA$21.76
See more pivots

Exelixis Inc Stock, NASDAQ:EXEL

1851 Harbor Bay Parkway, Alameda, California 94502
United States of America
Phone: +1.650.837.7000
Number of Employees: 1310

Description

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.